Report Scope:
This report aims to study the myasthenia gravis treatment global market size comprehensively. Current and historical market revenues can be estimated based on the product type, treatment by drug and region.
Report Includes:
- 54 data tables and 47 additional tables
- An overview and analysis of the global market for myasthenia gravis (MG) treatments
- Analyses of market trends, with historical market revenue data (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Estimates of the market size, revenue forecasts and potential growth share analysis for MG treatments based on product, type, treatment modality, and region
- In-depth information (facts and figures) pertaining to the major factors influencing the market (drivers, restraints, opportunities and challenges)
- Analysis of the market growth opportunities through Porter's Five Forces and PESTLE analyses, taking into consideration the prevailing micro- and macro environmental factors
- An examination of the importance of ESG in the myasthenia gravis market, taking into account consumer attitudes, risks and opportunities, and the ESG practices of pharmaceutical and biotech companies
- Discussion of the factors driving the market, industry trends and new developments
- Analysis of relevant patents
- Identification of the leaders in the field of MG
- Profiles of the leading market players, including Profiles of the leading market players, including AbbVie, Bausch Health, Gilead Sciences, Merck & Co. Inc., Servier, and Teva
Summary:
The market for myasthenia gravis (myasthenia gravis) treatments had an estimated value of $REDACTED billion in 2022 and is projected to grow to $REDACTED billion in 2028.
The global market for myasthenia gravis treatments was valued at nearly $REDACTED billion in 2022. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED%, reaching $REDACTED billion in 2028. Growth in this market is fueled by a worldwide increase in elderly populations and an increased prevalence of myasthenia gravis.
Technological innovation is an important catalyst driving adaptation and use.
In 2022, the generalized myasthenia gravis segment held the highest market share at about REDACTED%, followed by ocular myasthenia gravis at REDACTED% and transient neonatal myasthenia gravis at REDACTED%
Global Myasthenia Gravis Treatment Market: Forecast and Trends
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Information Sources
Primary Research
Secondary Research
Geographic Breakdown
Segmentation Breakdown
Chapter 2 Summary and Highlights
Market Outlook
Report Highlights
Chapter 3 Market Overview
Myasthenia Gravis
Ocular Myasthenia Gravis
Generalized Myasthenia Gravis
Transient Neonatal Myasthenia Gravis
Global Regulatory Structure for Myasthenia Gravis
Drug Approvals and Regulation
Clinical Trials
Patient Access and Health Insurance
Pharmaceutical Pricing and Reimbursement
Clinical Practice Guidelines
Rare Disease Designation
Patient Advocacy and Support
Pricing and Reimbursement for the Treatment of Myasthenia Gravis
North America
Europe
Asia-Pacific
Therapies/Drugs Used to Treat Myasthenia Gravis
Medications
Surgery
Intravenous (IV) Therapy
Medications
Chapter 4 Market Dynamics
Market Drivers
Growing Elderly Population
Increasing Incidence and Prevalence
Advancements in Myasthenia Gravis Diagnostics
Research and Development
Regulatory Environment
Personalized Medicine
Market Opportunities
Unmet Medical Needs
Advancements in Research and Development
Biologics and Immunotherapies
Global Expansion
Increased Awareness
Tailored Treatment Approaches
Healthcare Reimbursement
Patient-Centric Care
Competitive Landscape
Chronic Nature of Myasthenia Gravis
Research Collaboration
Market Restraints
Limited Patient Population
Diagnostic Challenges
Lack of Disease-Modifying Therapies
Reimbursement Issues
Risks of Emerging Therapies
Other Restraints
Chapter 5 Market Breakdown by Region
Market Overview
North America
Europe
Asia-Pacific
Chapter 6 Market Breakdown by Type
Market Overview
Generalized Myasthenia Gravis
Transient Neonatal Myasthenia Gravis
Ocular Myasthenia Gravis
Chapter 7 Market Breakdown by Treatment Modality
Introduction
Medications
Surgery
Intravenous Therapy
Chapter 8 Market Breakdown by Type of Product
Monoclonal Antibodies
Brands
Cholinesterase Inhibitors
Brand
Intravenous Immunoglobulins
Brands
Immunosuppressants
Brand
Corticosteroids
Brand
Chapter 9 ESG Development
Introduction
Environment
Social
Governance
Case Study
AstraZeneca
Concluding Remarks from BCC Research
Chapter 10 Emerging Technologies and Developments
Introduction
Chapter 11 Competitive Intelligence
Overview
Industry Scenario
Company Shares
Chapter 12 Patent Analysis
Patent Analysis by Manufacturer
Chapter 13 Pipeline Analysis
Clinical Trials
Chapter 14 M&A and Venture Funding Outlook
Introduction
Chapter 15 Company Profiles
ABBVIE
AMYASTHENIA GRAVISEN INC.
ASTELLAS PHARMA INC.
ASTRAZENECA
BAUSCH HEALTH COMPANIES INC.
BAYER AG
BIOGEN
BRISTOL-MYERS SQUIBB
CSL
DAIICHI SANKYO CO. LTD.
F. HOFFMANN-LA ROCHE AG
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC.
MERCK & CO. INC.
NOVARTIS
PFIZER INC.
SANOFI
SERVIER LABORATORIES
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Chapter 16 Appendix: Acronyms
List of Tables
Summary Table : Global Market for the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, Through 2028
Table 1 : Global Population, Aged 60+, 2010-2050
Table 2 : Factors Leading to the Increasing Incidence of Myasthenia Gravis Worldwide
Table 3 : Global Serological Testing for Myasthenia Gravis, by Type
Table 4 : Targeted Drug Therapies for the Treatment of Myasthenia Gravis
Table 5 : Diagnostic Challenges in the Treatment of Myasthenia Gravis
Table 6 : Risks of Emerging Therapies for Myasthenia Gravis, by Type
Table 7 : Global Market for the Treatment of Myasthenia Gravis, by Region, Through 2028
Table 8 : North American Market for the Treatment of Myasthenia Gravis, by Country, Through 2028
Table 9 : European Market for the Treatment of Myasthenia Gravis, by Country, Through 2028
Table 10 : Asia-Pacific Market for the Treatment of Myasthenia Gravis, by Country, Through 2028
Table 11 : Global Prevalence of Myasthenia Gravis, by Type
Table 12 : Global Market for the Treatment of Generalized Myasthenia Gravis, by Region, Through 2028
Table 13 : Global Market for the Treatment of Ocular Myasthenia Gravis, by Region, Through 2028
Table 14 : Global Market for the Treatment of Transient Neonatal Myasthenia Gravis, by Region, Through 2028
Table 15 : Global Market for Medications for the Treatment of Myasthenia Gravis, by Region, Through 2028
Table 16 : Global Market for Surgical Treatment of Myasthenia Gravis, by Region, Through 2028
Table 17 : Global Market for Intravenous Therapy for the Treatment of Myasthenia Gravis, by Region, Through 2028
Table 18 : Global Market for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 19 : Global Market for Monoclonal Antibodies for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 20 : Global Market for Cholinesterase Inhibitors for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 21 : Global Market for Intravenous Immunoglobulins for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 22 : Global Market for Immunosuppressants for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 23 : Global Market for Corticosteroids for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 24 : ESG Framework for the Global Pharmaceutical Industry
Table 25 : Social Framework of the Global Pharmaceutical Industry
Table 26 : Top Pharma Companies: ESG Ratings
Table 27 : AstraZeneca's Contribution to Sustainable Development Goals
Table 28 : AstraZeneca's Material Focus Areas
Table 29 : New Technologies for Myasthenia Gravis Treatments
Table 30 : New Pharmaceuticals for the Treatment of Myasthenia Gravis
Table 31 : Global Company Market Shares of Myasthenia Gravis Treatments, 2022
Table 32 : Global Product Shares of Myasthenia Gravis Treatments, by Brand, 2022
Table 33 : Global Sales of Myasthenia Gravis Treatments, by Brand, 2022
Table 34 : Key Financials of Pharma Companies Offering Myasthenia Gravis Treatment Products, 2022
Table 35 : Patents on Myasthenia Gravis Treatments, 2018-Present
Table 36 : Selected Manufacturer Patents on Myasthenia Gravis Drugs, 2018-Present
Table 37 : Patents on Eculizumab, 2018-Present
Table 38 : Selected Manufacturer Patents on Eculizumab, 2018-Present
Table 39 : Patents on Efgartigimod alfa, 2018-Present
Table 40 : Selected Manufacturer Patents on Efgartigimod alfa, 2018-Present
Table 41 : Patents on Rituximab, 2018-Present
Table 42 : Selected Manufacturer Patents on Rituximab, 2018-Present
Table 43 : Patents on Pyridostigmine, 2018-Present
Table 44 : Selected Manufacturer Patents on Pyridostigmine, 2018-Present
Table 45 : Patents on Privigen, 2018-Present
Table 46 : Selected Manufacturer Patents on Privigen, 2018-Present
Table 47 : Clinical Trials on Myasthenia Gravis, as of 2023
Table 48 : Mergers and Acquisitions, 2019-2021
Table 49 : AbbVie: Product Information
Table 50 : AbbVie: Financial Overview, 2020-2022
Table 51 : AbbVie: Key Developments, 2021-2023
Table 52 : Amgen: Revenue, 2020-2022
Table 53 : Amgen: Key Developments, 2021 and 2022
Table 54 : Astellas Pharma: Revenue, 2020-2022
Table 55 : Astellas Pharma: Key Developments, 2018-2022
Table 56 : AstraZeneca: Product Information
Table 57 : AstraZeneca: Revenue, 2020-2022
Table 58 : AstraZeneca: Key Developments, 2022 and 2023
Table 59 : Bausch Health: Product Information
Table 60 : Bausch Health: Revenue, 2020-2022
Table 61 : Bayer AG: Product Information
Table 62 : Bayer AG: Financial Overview, 2020-2022
Table 63 : Bayer AG: Key Developments, 2022 and 2023
Table 64 : Biogen: Financial Overview, 2020-2022
Table 65 : Biogen: Key Developments, 2018-2023
Table 66 : Bristol-Myers Squibb: Product Information
Table 67 : Bristol-Myers Squibb: Financial Overview, 2020-2022
Table 68 : Bristol-Myers Squibb: Key Developments, 2021-2023
Table 69 : CSL: Product Information
Table 70 : CSL: Revenue, 2020-2022
Table 71 : CSL: Recent Developments, 2022
Table 72 : Daiichi Sankyo: Product Information
Table 73 : Daiichi Sankyo: Financial Overview, 2020-2022
Table 74 : Daiichi Sankyo: Key Developments, 2022 and 2023
Table 75 : Roche: Product Information
Table 76 : Roche: Revenue, 2020-2022
Table 77 : Roche: Key Developments, 2021-2023
Table 78 : Gilead Sciences: Financial Overview, 2020-2022
Table 79 : Gilead Sciences: Key Developments, 2022
Table 80 : GlaxoSmithKline plc: Product Segments
Table 81 : GlaxoSmithKline plc: Financial Overview, 2020-2022
Table 82 : GlaxoSmithKline plc: Recent Developments, 2022
Table 83 : Merck & Co. Inc.: Business Segments
Table 84 : Merck & Co. Inc.: Financial Overview, 2020-2022
Table 85 : Merck & Co. Inc.: Key Developments, 2022
Table 86 : Novartis: Product Information
Table 87 : Novartis: Financial Overview, 2020-2022
Table 88 : Novartis: Key Developments, 2023
Table 89 : Pfizer Inc: Product Segments
Table 90 : Pfizer Inc: Financial Overview, 2020-2022
Table 91 : Pfizer Inc: Top Brands, 2022
Table 92 : Pfizer Inc: Key Developments, 2019-2023
Table 93 : Sanofi: Business Segments
Table 94 : Sanofi: Annual Revenue, 2020-2022
Table 95 : Sanofi: Key Developments, 2021-2023
Table 96 : Servier: Annual Revenue, 2020-2022
Table 97 : Servier: Key Developments, 2022 and 2023
Table 98 : Teva: Financial Overview, 2020-2022
Table 99 : Teva: Key Developments, 2021-2023
Table 100 : Acronyms
List of Figures
Summary Figure A : Global Market for the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, 2020-2028
Summary Figure B : Global Market Shares of the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, 2022
Figure 1 : Global Factors Leading to the Prevalence of Myasthenia Gravis, by Region, 2022
Figure 2 : Global Market Shares of Myasthenia Gravis Treatments, by Region, 2022
Figure 3 : North American Market Shares of Myasthenia Gravis Treatments, by Country, 2022
Figure 4 : European Market Shares of Myasthenia Gravis Treatments, by Country, 2022
Figure 5 : Asia-Pacific Market Shares of Myasthenia Gravis Treatments, by Country, 2022
Figure 6 : Global Distribution of Types of Myasthenia Gravis, 2022
Figure 7 : Global Market Shares of Myasthenia Gravis Treatments, by Treatment Modality, 2022
Figure 8 : Global Market Shares of Myasthenia Gravis Treatments, by Type of Product, Through 2022
Figure 9 : Global Electricity Production from Renewable Sources, 2017-2021
Figure 10 : Global Recycled Waste, 2017-2021
Figure 11 : Global CO2 Emissions, 2017-2021
Figure 12 : Global Company Market Shares of Myasthenia Gravis Treatments, 2022
Figure 13 : Global Sales of Myasthenia Gravis Treatments, by Brand, 2022
Figure 14 : AbbVie: Revenue Shares, by Country, 2022
Figure 15 : Bristol-Myers Squibb: Revenue Share, by Country/Region, 2022
Figure 16 : Daiichi Sankyo: Market Share, by Country/Region, 2022
Figure 17 : Gilead Sciences: Revenue, by Type of Product, 2022
Figure 18 : GlaxoSmithKline plc: Annual Revenue, by Segment, 2022
Figure 19 : Merck & Co. Inc.: Annual Revenue, Pharmaceutical Segment, 2022
Figure 20 : Novartis Innovative Medicines: Market Share, by Country/Region, 2022
Figure 21 : Novartis Sandoz: Market Share, by Country/Region 2022
Figure 22 : Sanofi: Revenue, by Region, 2022
Figure 23 : Sanofi: Revenue, by Segment, 2022
Figure 24 : Teva: Market Share, by Region, 2022
Global Antioxidant Vitamins Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 100
The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
Global Clavulanate Potassium Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 86
The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030.
North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
Global Amoxicillin Sodium Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 84
The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030.
North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
Global Melatonin Supplements Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 106
The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 93
The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
Global Sleeping Pills Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 94
The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
Global Zinc Oral Drops Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
Global Zinc Drops Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
Global Anti-Infectives Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 78
The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
